June 2012

Dear Colleagues: 

Many important messages/announcements will be found in this Newsletter: The search for a new CEO for the organization has started and has been announced. As mentioned earlier, Dr. Paul Bunn Jr, MD, after many years in office, having brought this organization to another level, is stepping down at the WLCC in Sydney 2013. The IASLC Board is searching for his successor (see below). The search for a Chief Editor for our journal JTO is now in its final round. 

Please note several important upcoming scientific meetings and consider participating. The Latin-American Lung Cancer Conference (LALCA) will be held in Rio de Janeiro, July 25-28, 2012; we hope that as many of our Latin-American members as possible will join. The ASTRO/ASCO/IASLC/University of Chicago Multidisciplinary Conference will be held in Chicago, September 6-8, 2012; a very exciting program has been established. For The Asian Pacific Lung Cancer (APLCC) Meeting in Fukuoka, Japan, November 25-28.2012 the abstract submission is still open! 

The IASLC is expanding their fellowship program and we are proud to announce in this Newsletter a one-year Fellowship in China (see below). 

Many new educational activities are established and planned. The IASLC Webinar series is expanding and a webinar on “implementation of the new IASLC Adenocarcinoma Classification has been launched. 

IASLC has also joined College of American Pathologists (CAP) and American Society of Molecular Pathology (AMP) in developing guidelines for molecular testing for EGFR mutations and ALK-gene rearrangements. The guidelines are currently in the final approval process and are expected to be launched within a few months with an accompanying webinar series as well. 

The IASLC is also currently working on establishing regional offices in order to facilitate our regional activities; the Executive Committee has approved the establishment of the first regional office in Hong Kong starting in 2013. 

Many new committees have been established within IASLC in order to implement the strategic planning. In the future, the Newsletter will separately feature the ongoing work of each of the committees. Among the new committees, an Industry Task Force Committee was established under the chairmanship of Dr. Stahel and a first meeting was held during the recent annual ASCO meeting in Chicago. A very constructive dialogue between representatives for pharmaceutical and diagnostic companies and IASLC representatives was initiated, and follow-up meetings and subcommittees were planned (more details in future Newsletters). 

The IASLC Board and Headquarters wish all a healthy and happy summer season! 

Fred R. Hirsch, MD, PhD 

Editor, IASLC Newsletter 

Editor Search: Journal of Thoracic Oncology (JTO) 

The International Association for the Study of Lung Cancer (IASLC) has opened its search for candidates for a five-year term as Editor-in-Chief of the Journal of Thoracic Oncology. The Editor is responsible for oversight of each monthly issue and all supplements. The Editor works remotely from IALSC offices and with the publisher. The transition will begin Oct. 2012 with full responsibility on Jan. 1, 2013. 

In addition to being an IASLC member, the successful candidate will: 

  • Be a recognized thoracic oncology thought leader 
  • Be a proven scientific investigator in thoracic oncology 
  • Have editorial experience or large-team leadership experience 
  • Be able to meet the time demands of the Editor-in-Chief position 
  • Have broad scientific and thoracic oncology interests and the ability to recognize scientific quality and innovation 
  • Possess a high degree of integrity 

Inquiries and submissions should be sent to: 

Chair of the Editor Search Committee 

c/o IASLC Executive Office 

13100 E Colfax Ave Unit 10 

Aurora, CO 80011 

Or send documents electronically to: 

More information can be found on the IASLC website, 

Submissions should be delivered by July 1, 2012 and include a letter of interest, a one-to two-page vision statement for the Journal of Thoracic Oncology and curriculum vitae. 

Final interviews are scheduled for Saturday, Sept. 8 in Chicago, Illinois with the Search Committee and Board of Directors. 

IASLC Chief Executive Officer 

The International Association for the Study of Lung Cancer (IASLC) has opened its search for candidates for Chief Executive Officer (CEO). The CEO serves as the leader of the IASLC, representing the organization in all internal and external activities. The CEO reports to the President and the Board of Directors and is responsible for ensuring that the IASLC activities set by the Board are carried out. The CEO is responsible for ensuring that the IASLC reaches the mission, goals and strategic plan set forth by the Board of Directors. 

The CEO is responsible for providing strategic leadership for the IASLC by working with the Board of Directors and the management team to establish long-range goals, strategies, plans and policies in support of the IASLC mission to: 

  • Promote the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies; 
  • Disseminate information about lung cancer and other thoracic malignancies to the members of the Association, to the medical community at large, and to the public; and, 
  • Use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world. 

The IASLC Executive offices are located in Aurora, Colo. It is expected that the CEO will spend at least 75 percent effort in his/her role of CEO of the IASLC. With Board approval, the CEO may spend the remainder of his/her working week in other academic/clinical positions related to thoracic oncology. This may include a part time appointment in an academic or other institution approved by the Board. The CEO must be in regular contact with the Executive Office, but may live and have an academic appointment at a location outside of Colorado and the USA with Board approval. 

Principal Duties 

1. Works effectively with the Board to support the IASLC’s mission, goals and strategic plan. 

2. Works with the Board to develop, monitor and revise the strategic plan. 

3. Works with the Board and staff to secure funding and sponsorship for all IASLC activities. 

4. Provides leadership and management to ensure that the mission, vision and core values of the IASLC are developed, communicated and implemented. 

5. Responsible for leading the IASLC to achieve and surpass membership, educational, research and financial goals and objectives. 

6. Spearheads the development, communication and implementation of effective growth strategies and processes. 

7. Collaborates with the management team to develop and implement plans for the operational infrastructure of systems, processes and personnel designed to accommodate the growth objectives of the IASLC. 

8. Motivates and leads a high-performance management team, attracts, recruits and retains required staff and provides appropriate mentoring for their success. 

9. Represents the IASLC with members, donors and other partners. 

10. Establishes credibility throughout the IASLC and with the Board of Directors as an effective developer of solutions to management, mission and other challenges. 

11. Fosters a success-oriented, accountable environment within the organization. 

12. Oversees the IASLC activities of the COO/CFO and other staff. 

Position Requirements 

The CEO is expected to be a physician member of the IASLC and who has a career focus on thoracic oncology. More than 10 years of experience in oncology activities, leadership activities and administrative activities are required. 

To perform the job successfully, an individual should demonstrate the following competencies to perform the essential functions of this position. 

• Leadership— proven success in leading, inspiring, motivating, and managing other professionals; personal creativity and strategic vision, coupled with an ability to listen to others and learn from their best ideas; 

• Management skills— demonstrated ability to inspire trust, organize people into effective teams and motivate them to work well together; includes staff in planning, decision-making, facilitating and process improvement; makes self available to staff; provides regular performance feedback; and develops subordinates’ skills and encourages growth; 

• Delegation—delegates work assignments and gives authority to work independently; sets expectations and monitors delegated activities; 

• Demonstrated management acumen— proven record in maintaining or increasing organizational viability and effectiveness, and comfort in 

dealing with the budgeting process and management of staff and financial resources; 

• Demonstrated fundraising ability, particularly with individuals, endowments and foundations and a willingness to try new ideas in fundraising; 

• Judgment—displays a willingness to make decisions, exhibits sound and accurate judgment, and makes timely decisions; 

• Communications—communicates clearly and persuasively, both orally and in writing, in positive or negative situations; demonstrates group presentation skills and conducts productive meetings; 

• Analytical—synthesizes complex and diverse information; 

• Problem solving—identifies and resolves problems in a timely manner and gathers and analyzes information skillfully; 

• Quality management—looks for ways to improve and promote quality and demonstrates accuracy and thoroughness; 

• Planning/organizing—prioritizes and plans work activities, uses time efficiently and develops realistic action plans. 

Minimum Qualifications 

1. Must be a physician member in good standing in the IASLC. 

2. Demonstrated effectiveness with interpersonal and public relations essential. 

3. High level of attention to planning, execution and details. 

4. Must be experienced with international meetings of all sizes. 

5. Must possess the ability to balance the needs and desires of multiple constituencies and cultures. 

6. Must exhibit great diplomacy in guiding members and leaders from varying cultures and languages, and with diverse agendas and skill levels, to agree on the most logical and beneficial actions that will ensure the success of IASLC and the achievement of its mission. 

7. Leadership experience in nonprofit or philanthropic organizations such as service on the executive, board or committee member, preferably having served in several elected or appointed offices at international level. 

8. Requires proficiency in English and experience with presentations to audiences of varying sizes and make-up. 

9. Should be seen as a recognized leader within the field of lung cancer/thoracic malignancies research and treatment. 

Inquiries and submissions should be sent to: 

IASLC Search Committee 

Send documents electronically to: 

More information can be found on the IASLC website, 

Submission should be delivered by Sept. 15, 2012 and include a letter of interest, a one- to two-page vision statement, a curriculum vitae and a plan of how to effectively engage and manage IASLC staff in Denver. 

Please remember to pay the IASLC membership fee 2012 - $200 

Registering online is fast and easy! Visit for more information. 

IASLC members will be sent renewal reminders and invoices. Register now so there will no interruption to your JTO subscription, and to receive discounts on 2012 meeting fees. Please contact the Membership Department if you need any assistance paying your dues: 

FREE IASLC Membership for Fellows: Did you know that IASLC offers a FREE membership for fellows? This complimentary membership includes online access to the JTO, as well as additional discounts and educational programs. It is a great way to expose clinical fellows to the benefits of IASLC membership and introduce them to IASLC activities. The complimentary Fellow membership is available for a maximum of two years, and requires a verification letter from the program director stating the term dates of the fellowship. Please forward this link to any fellows you know and encourage them to join immediately:

5th Latin American Conference on Lung Cancer 

The 5th Latin American Conference is now under planning and both an exciting educational – and scientific program have been developed, including sessions on the new staging, lung cancer screening and molecular testing for personalized medicine. For more information or 




2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, September 6-8, 2012 

5th APLCC ITMIG IASLC Conference, November 26-28, 2012 

Abstract submission is open – please go to for more information 

Boehringer Ingelheim IASLC Chinese Research Fellowship Award 1 year duration 

The IASLC is proud to announce the Boehringer Ingelheim IASLC Chinese Research Fellowship Award. There is one award for one year for a Chinese applicant to be funded with $40,000

We are now requesting application for this Fellowship award to be awarded in 2012 - 2013. The goal is to reward scientific excellence and to encourage innovative investigations in the field of lung cancer prevention research and translational research with a potential impact on the management of lung cancer. The applications will be evaluated by a Scientific Review Panel; the deadline for submission of the application is July 15, 2012. A decision on applications will be reached by August 15, 2012. 

Application forms can be found at the website: 

Please e-mail you application to: latest July 15, 2012 

IASLC Web-based Education Programs 

IASLC has introduced new educational programs on its Web site ( for its members and for healthcare professionals who are managing patients with lung cancer. The first program titled, “New Developments in Non-Small Cell Lung Cancer” features Professor Peter Goldstraw, MD, in a two-part presentation, that reviews the fundamentals of the new lung cancer staging system and examines the role of the TNM staging system of patients with small-cell lung cancer. The new, updated IASLC nodal staging map is also reviewed. In another presentation, Paul Bunn, Jr, MD, addresses the incorporation of molecular testing into the standard diagnostic workup of patients with NSCLC, and the selection of appropriate treatment for patients. The program concludes with case-study presentations by Drs. Bunn and Harvey I. Pass, illustrating the use of the new staging system and molecular testing. 

Upcoming webinars include: “Clinical Implications of the New Adenocarcinoma Classification” 

Women and Lung Cancer - CME-certified Audio-guided Web course 

The International Association for the Study of Lung Cancer (IASLC) has partnered with joint sponsors Penn State College of Medicine and Rockpointe to bring a CME-certified webcourse to oncologists caring for patients with lung cancer. 

Joan H. Schiller, MD chairs the program with faculty Edward Garon, MD and Heather Wakelee, MD. Program Description: The treatment of NSCLC has been revolutionized in the past decade, with an increased understanding of the need for individualization of therapy. Histologic and molecular features of NSCLC predict response to targeted agents and certain chemotherapies. Gender should 

also play a role in treatment, as lung cancer biology, natural history, and treatment outcomes vary between men and women. 

This educational initiative was designed to help community oncologists integrate personalization of therapy into the treatment of NSCLC patients. The goal is to enhance knowledge, clinical competence, and performance of clinicians with respect to diagnosis, staging, and treatment options – thereby leading to improved patient outcomes. The activity is supported by an educational grant from Lilly, USA and Genentech BioOncology. 

Click here to view activity: 

IASLC Staging Manual: 

The IASLC Staging Manual and Handbook in Thoracic Oncologic has now surpassed 35,000 copies sold worldwide. In addition, the Staging Posters and Reference Cards continue to be popular reference aids of the 7th edition staging system for practitioners and tumor boards. IASLC members can continue to order these publications and products at special member pricing (; contact for further information). 

In addition, translations of these publications have been completed or are in process in multiple languages: Chinese, Italian, Japanese, Polish, and Turkish. Discussions about future translations in Spanish, Arabic, and Russian are ongoing. 

The new IASLC Staging Manual has been published in different formats. Several years of work from the IASLC Staging Committee and particularly the chair Dr. Peter Goldstraw, has resulted in a formal staging manual. The book and the “pocket-cards” can be ordered at




iPhone/iPad Staging Atlas 




Edward S. Kim, MD, is moving from The University of Texas MD Anderson Cancer Center in Houston Dr. Kim will be joining Derek Raghavan MD, PhD (President of the Levine Cancer Institute). Future contact information: Edward S. Kim, M.D., Chair, Dept of Solid Tumor Oncology and Investigational Therapeutics Donald S. Kim Distinguished Chair for Cancer Research Levine Cancer Institute, Carolinas Healthcare System, 

Charlotte, NC. 




 Upcoming IASLC Workshops/Meetings 2012- 2015 

13th Central European Lung Cancer Conference 

Prague, Czech Republic 

June 24 – 27, 2012 


3rd International Conference in Thoracic Oncology 

Naples, Italy 

June 28-30, 2012 


13th International Lung Cancer Congress 

Huntington Beach, CA 

July 19-22, 2012 


5th Latin American Lung Cancer Conference 

July 25-27, 2012 

Location: Rio de Janeiro, Brazil 

More information: 

Australian Lung Cancer Conference 

Adelaide, South Australia 

August 23-25, 2012 

More information: 

Chicago Multidisciplinary Symposium in Thoracic Oncology 

September 6-8, 2012 

Location: Hotel Marriott, Chicago, Illinois, U.S.A. 

More information: 

3rd International thoracic Oncology Congress 

Dresden, Germany 

September 13-15, 2012 


5th Asia Pacific Lung Cancer Conference 

November 26-28, 2012 Location: Hilton Sea Hawk, Fukuoka, Japan 

More information: 


15th World Conference on Lung Cancer 

October 27-31, 2013 

Location: Sydney, Australia 

More information: 


16th World Conference on Lung Cancer 

September 4-8, 2015 

Location: Denver, Colorado, USA 

More information: